| Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis AR Mato, C Nabhan, MC Thompson, N Lamanna, DM Brander, B Hill, ... Haematologica 103 (5), 874, 2018 | 435 | 2018 |
| Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B … NE Kay, SM Geyer, TG Call, TD Shanafelt, CS Zent, DF Jelinek, ... Blood 109 (2), 405-411, 2007 | 359 | 2007 |
| Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia TD Shanafelt, TE Witzig, SR Fink, RB Jenkins, SF Paternoster, SA Smoley, ... Journal of Clinical Oncology 24 (28), 4634-4641, 2006 | 302 | 2006 |
| Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia MR Grever, O Abdel-Wahab, LA Andritsos, V Banerji, J Barrientos, ... Blood, The Journal of the American Society of Hematology 129 (5), 553-560, 2017 | 271 | 2017 |
| Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients AR Mato, BT Hill, N Lamanna, PM Barr, CS Ujjani, DM Brander, C Howlett, ... Annals of Oncology 28 (5), 1050-1056, 2017 | 266 | 2017 |
| Diffuse large B‐cell lymphoma (R ichter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients SA Parikh, KG Rabe, TG Call, CS Zent, TM Habermann, W Ding, JF Leis, ... British journal of haematology 162 (6), 774-782, 2013 | 253 | 2013 |
| Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia P Thurmes, T Call, S Slager, C Zent, G Jenkins, S Schwager, D Bowen, ... Leukemia & lymphoma 49 (1), 49-56, 2008 | 242 | 2008 |
| Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience AR Mato, C Nabhan, PM Barr, CS Ujjani, BT Hill, N Lamanna, ... Blood, The Journal of the American Society of Hematology 128 (18), 2199-2205, 2016 | 216 | 2016 |
| Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia TD Shanafelt, TG Call, CS Zent, B LaPlant, DA Bowen, M Roos, ... Journal of Clinical Oncology 27 (23), 3808-3814, 2009 | 209 | 2009 |
| CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential TD Shanafelt, SM Geyer, ND Bone, RC Tschumper, TE Witzig, ... British journal of haematology 140 (5), 537-546, 2008 | 207 | 2008 |
| Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia TD Shanafelt, T Lin, SM Geyer, CS Zent, N Leung, B Kabat, D Bowen, ... Cancer 109 (11), 2291-2298, 2007 | 207 | 2007 |
| Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia TD Shanafelt, TG Call, CS Zent, JF Leis, B LaPlant, DA Bowen, M Roos, ... Cancer 119 (2), 363-370, 2013 | 189 | 2013 |
| Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia TD Shanafelt, MT Drake, MJ Maurer, C Allmer, KG Rabe, SL Slager, ... Blood, The Journal of the American Society of Hematology 117 (5), 1492-1498, 2011 | 174 | 2011 |
| Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients TD Shanafelt, D Bowen, C Venkat, SL Slager, CS Zent, NE Kay, ... British journal of haematology 139 (2), 255-264, 2007 | 171 | 2007 |
| Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States AR Mato, M Thompson, JN Allan, DM Brander, JM Pagel, CS Ujjani, ... Haematologica 103 (9), 1511, 2018 | 169 | 2018 |
| Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia TD Shanafelt, NE Kay, KG Rabe, TG Call, CS Zent, K Maddocks, ... Journal of Clinical Oncology 27 (24), 3959-3963, 2009 | 169 | 2009 |
| Bone marrow stromal cells protect lymphoma B‐cells from rituximab‐induced apoptosis and targeting integrin α‐4‐β‐1 (VLA‐4) with natalizumab can overcome this resistance M Mraz, CS Zent, AK Church, DF Jelinek, X Wu, S Pospisilova, SM Ansell, ... British journal of haematology 155 (1), 53-64, 2011 | 155 | 2011 |
| Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia TD Shanafelt, KG Rabe, NE Kay, CS Zent, DF Jelinek, MS Reinalda, ... Cancer 116 (20), 4777-4787, 2010 | 153 | 2010 |
| Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data CS Zent, MJ Kyasa, R Evans, SA Schichman Cancer: Interdisciplinary International Journal of the American Cancer …, 2001 | 153 | 2001 |
| B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome TD Shanafelt, NE Kay, G Jenkins, TG Call, CS Zent, DF Jelinek, ... Blood, The Journal of the American Society of Hematology 113 (18), 4188-4196, 2009 | 143 | 2009 |
